Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from kneat.com ( (TSE:KSI) ) is now available.
Kneat.com has signed a Master Services Agreement with a U.S.-headquartered global pharmaceutical packaging and drug-delivery manufacturer that operates more than 45 plants worldwide and employs over 13,000 people. The customer will initially roll out Kneat Gx for Commissioning, Qualification, and Validation at a lead site, with plans to expand deployment to all GMP-regulated facilities.
The win was driven by Kneat’s strong data integrity capabilities, which ensure validation records are fully attributable, traceable, and audit-ready in line with regulatory demands. The deal marks Kneat’s second strategic customer addition of 2026, reinforcing its position as a de facto standard for digital validation in life sciences and underscoring the resilience and long-term relevance of its platform as companies modernize quality systems.
The most recent analyst rating on (TSE:KSI) stock is a Hold with a C$4.50 price target. To see the full list of analyst forecasts on kneat.com stock, see the TSE:KSI Stock Forecast page.
Spark’s Take on TSE:KSI Stock
According to Spark, TipRanks’ AI Analyst, TSE:KSI is a Neutral.
Kneat.com’s overall stock score reflects strong SaaS revenue growth and high customer satisfaction, which are offset by profitability challenges and cash flow constraints. The technical indicators suggest a bearish trend, and the valuation is unattractive due to a negative P/E ratio. Strategic investments in R&D are promising, but increased operating expenses and macroeconomic headwinds pose risks.
To see Spark’s full report on TSE:KSI stock, click here.
More about kneat.com
Kneat Solutions is a provider of digital validation and quality process automation software for highly regulated industries, including pharmaceuticals, biotechnology, medical devices, and supply-chain manufacturing. Its flagship platform, Kneat Gx, enables end-to-end management of validation disciplines and is ISO 9001 and ISO 27001 certified, fully validated, and compliant with 21 CFR Part 11 and Annex 11, with independent studies showing substantial reductions in validation man-hours and faster review cycles.
Average Trading Volume: 149,100
Technical Sentiment Signal: Sell
Current Market Cap: C$392.7M
See more insights into KSI stock on TipRanks’ Stock Analysis page.